CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc.(NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today reported financial results for the three and six months ended June 30, 2015, and provided an update of recent corporate developments.
“We made significant achievements from both a regulatory and clinical perspective this quarter and look to build on this momentum as we continue through the regulatory process for eteplirsen, our lead product candidate,” said Edward Kaye, M.D., Sarepta’s interim chief executive officer and chief medical officer.
Help employers find you! Check out all the jobs and post your resume.
